scientific and microscope

Our clinical studies

We are committed to make our Clinical trials Information and Results accessible and transparent while maintaining participants privacy.

 

Clinical studies

This site provides information on both ongoing and completed clinical trials sponsored by Pierre Fabre since 2004. Real-world evidence studies which began after 01 January 2020 are also accessible.

 

Total studies

0

Current studies

0

Oncology

0

Dermatology

0

Rare diseases

0

Others

0
Show more filters
Title Therapeutic area Phase Status Start date (Planned) End date

Randomised phase II study of the combination of oral vinorelbine with capecitabine versus a sequential regimen of oral vinorelbine and capecitabine versus the combination of docetaxel and capecitabine...

Oncology Phase II Completed 03 June 2005 09 December 2010

Oral Vinorelbine and Cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral Vinorelbine and Cispalatine plus best supportive care or best supportive care alone in stage III Non Small Cell Lung Cancer (NSCLC): randomized Phase III study

Oncology Phase III Early termination 02 May 2005 09 May 2012

Efficacy and safety of 0,1%, 0,5% and 1% TAZAROTENE nail lacquer formulation versus vehicle in nail psoriasis. International, multicenter, double-blind, randomized study of four parallel groups

Dermatology Phase II Completed 28 April 2005 08 May 2006

Cross over comparison of Testosterone serum levels in Hypogonadal men treated with L0074 Testosterone Patch 60 cm2 (2 patches/48H) and oral Testosterone Undecaoate -PANTESTONE® 40mg- (2 caps, bid)

Hormonal Phase III Completed 16 March 2005 19 September 2005

Phase II trial of oral vinorelbine in combination with capecitabine as first line therapy in women with previously untreated HER2 negative metastatic breast cancer

Oncology Phase II Completed 08 November 2004 03 November 2007

A Randomised Phase II study of Oral Vinorelbine or I.V. Vinorelbine in patients with metastatic breast cancer previously treated with anthracyclines

Oncology Phase II Completed 30 September 2004 01 June 2007

Ensayo clínico en fase I-II de vinorelbina oral (Navelbine) en combinación con capecitabina en tratamiento de primera línea en pacientes con cáncer de mama avanzado

Oncology Phase I Completed 28 September 2004 14 October 2009

Efficacy of the topic RV3131A-HC3221 in the prevention of polymorphic light eruption

Dermatology Phase II Completed 28 September 2004 14 February 2006

Phase II study of oral vinorelbine in combination with capecitabine in metastatic breast cancer patients previously treated with anthracyclines and taxanes

Oncology Phase II Completed 08 September 2004 19 December 2007

Phase II trial of oral vinorelbine in combination with capecitabine and trastuzumab as first line therapy in women with previously untreated HER2 positive metastatic breast cancer

Oncology Phase II Completed March 2004 21 May 2019

Prospective randomised clinical phase III trial of (alternating IV and oral) vinorelbine plus cisplatin versus docetaxel plus cisplatin in first line chemotherapy of locally advanced or metastatic non...

Oncology Phase III Completed 02 February 2004 01 January 2006

Get access to Partner's pivotal studies supporting our authorized drugs in Europe

Results from pivotal studies conducted by our partners and supporting a marketing approval for whom Pierre Fabre is the holder in Europe are shared below:

 

Melanoma

SPONSOR: PFIZER

Breast cancer 

SPONSOR: PUMA BIOTECHNOLOGY

Colorectal cancer

SPONSOR: PFIZER

Post-transplantation lymphoproliferative disease EBV+

SPONSOR: ATARA